DK3133070T3 - Eliglustat (genz 112638) som inhibitor af glucosylceramidsyntase til anvendelse i en fremgangsmåde til behandling af fabrys eller gauchers sygdom, hvilken fremgangsmåde omfatter justering af den individuelle terapeutiske dosis i forhold til patientens p-450-metabolisme - Google Patents

Eliglustat (genz 112638) som inhibitor af glucosylceramidsyntase til anvendelse i en fremgangsmåde til behandling af fabrys eller gauchers sygdom, hvilken fremgangsmåde omfatter justering af den individuelle terapeutiske dosis i forhold til patientens p-450-metabolisme Download PDF

Info

Publication number
DK3133070T3
DK3133070T3 DK16175117T DK16175117T DK3133070T3 DK 3133070 T3 DK3133070 T3 DK 3133070T3 DK 16175117 T DK16175117 T DK 16175117T DK 16175117 T DK16175117 T DK 16175117T DK 3133070 T3 DK3133070 T3 DK 3133070T3
Authority
DK
Denmark
Prior art keywords
eliglustate
gauch
genz
factory
inhibitor
Prior art date
Application number
DK16175117T
Other languages
English (en)
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3133070(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK3133070T3 publication Critical patent/DK3133070T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
DK16175117T 2009-11-27 2010-11-24 Eliglustat (genz 112638) som inhibitor af glucosylceramidsyntase til anvendelse i en fremgangsmåde til behandling af fabrys eller gauchers sygdom, hvilken fremgangsmåde omfatter justering af den individuelle terapeutiske dosis i forhold til patientens p-450-metabolisme DK3133070T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27
EP14164650.5A EP2796457B1 (en) 2009-11-27 2010-11-24 Genz 112638 for treating Gaucher or Fabry disease in combination therapy

Publications (1)

Publication Number Publication Date
DK3133070T3 true DK3133070T3 (da) 2019-11-11

Family

ID=43431870

Family Applications (3)

Application Number Title Priority Date Filing Date
DK14164650.5T DK2796457T3 (da) 2009-11-27 2010-11-24 Genz 112638 til behandling af Gauchers eller Fabrys sygdom ved kombinationsbehandling
DK10785289.9T DK2504332T4 (da) 2009-11-27 2010-11-24 Amorf form og krystallinsk form af genz 112638-hemitartrat som inhibitor af glucosylceramidsyntase
DK16175117T DK3133070T3 (da) 2009-11-27 2010-11-24 Eliglustat (genz 112638) som inhibitor af glucosylceramidsyntase til anvendelse i en fremgangsmåde til behandling af fabrys eller gauchers sygdom, hvilken fremgangsmåde omfatter justering af den individuelle terapeutiske dosis i forhold til patientens p-450-metabolisme

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK14164650.5T DK2796457T3 (da) 2009-11-27 2010-11-24 Genz 112638 til behandling af Gauchers eller Fabrys sygdom ved kombinationsbehandling
DK10785289.9T DK2504332T4 (da) 2009-11-27 2010-11-24 Amorf form og krystallinsk form af genz 112638-hemitartrat som inhibitor af glucosylceramidsyntase

Country Status (41)

Country Link
US (6) US11458119B2 (da)
EP (5) EP3599237B1 (da)
JP (6) JP2013512252A (da)
KR (5) KR20180049255A (da)
CN (5) CN105753846B (da)
AR (3) AR079152A1 (da)
AU (3) AU2010324810B2 (da)
BR (1) BR112012012947B8 (da)
CA (3) CA3075788C (da)
CL (2) CL2012001348A1 (da)
CR (1) CR20120277A (da)
CY (3) CY1115880T1 (da)
DK (3) DK2796457T3 (da)
DO (2) DOP2012000141A (da)
EA (3) EA029990B1 (da)
EC (2) ECSP12011926A (da)
ES (4) ES2586947T3 (da)
GT (1) GT201200161A (da)
HK (2) HK1172031A1 (da)
HR (3) HRP20140780T4 (da)
HU (2) HUE029371T2 (da)
IL (4) IL310635A (da)
LT (2) LT2796457T (da)
MA (1) MA33838B1 (da)
ME (1) ME02477B (da)
MX (1) MX358345B (da)
MY (2) MY160542A (da)
NI (1) NI201200096A (da)
NZ (3) NZ600155A (da)
PE (2) PE20121337A1 (da)
PH (1) PH12015502514A1 (da)
PL (4) PL3599237T3 (da)
PT (4) PT2796457T (da)
RS (3) RS54978B1 (da)
SG (2) SG10201800136QA (da)
SI (3) SI2796457T1 (da)
SM (1) SMT201600273B (da)
TN (1) TN2012000237A1 (da)
TW (3) TWI656873B (da)
UA (1) UA113491C2 (da)
WO (1) WO2011066352A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
US9155784B2 (en) * 2011-06-20 2015-10-13 Icahn School Of Medicine At Mount Sinai Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
HUE051021T2 (hu) 2011-09-07 2021-01-28 Sinai School Medicine Ceramidáz és sejtek differenciálódása
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
EP2854910B1 (en) 2012-06-01 2020-04-15 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
US9937246B2 (en) 2013-03-14 2018-04-10 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
EP3046920B1 (en) * 2013-09-20 2021-08-04 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2016001885A2 (en) * 2014-07-03 2016-01-07 Dr. Reddy’S Laboratories Limited Amorphous form of eliglustat hemitartarate
ES2716420T3 (es) 2015-04-14 2019-06-12 Sandoz Ag Clorhidrato de eliglustat cristalino
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US11116755B2 (en) 2015-11-18 2021-09-14 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) * 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
KR20200016969A (ko) * 2017-06-16 2020-02-17 베타 파마, 인크. N-(2-(2-(디메틸아미노)에톡시)-4-메톡시-5-((4-(1-메틸-1h-인돌-3-일)피리미딘-2-일)아미노)페닐)아크릴아미드 및 그의 염의 제약 제제
US20200222310A1 (en) * 2017-08-08 2020-07-16 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
US20200197366A1 (en) * 2017-08-08 2020-06-25 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
WO2019118707A1 (en) 2017-12-15 2019-06-20 Genzyme Corporation Methods for treating gaucher disease
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
US11760741B2 (en) 2018-05-02 2023-09-19 Kashiv Biosciences, Llc Pro-drugs of eliglustat
US20210113703A1 (en) * 2018-05-27 2021-04-22 Bioasis Technologies Inc. Treatment of gaucher disease
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
DK0742789T3 (da) 1994-02-02 2000-11-13 Liposome Co Inc Farmaceutisk aktive forbindelser og liposomer og fremgangsmåder til anvendelse af disse
EP0765865B1 (en) 1994-06-10 2001-12-12 Seikagaku Corporation 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
EP1098642B1 (en) 1998-07-27 2007-04-04 Johns Hopkins University Diamino-propanol-compounds for treating ischemia
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
JP2003521479A (ja) * 1999-07-09 2003-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
DE20122435U1 (de) 2000-04-24 2005-10-06 Teva Pharmaceutical Industries Ltd. Mikronisiertes Zolpidem-Hemitartrat
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP2004531478A (ja) 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
MXPA03006294A (es) * 2001-01-18 2003-09-16 Merck Patent Gmbh Proteinas de fusion disfuncionales con actividad glucocerebrosidasa.
DK2067775T3 (da) 2001-07-16 2012-07-16 Genzyme Corp N-acylsphingosinglucosyltransferase-inhibitor
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
JP4316203B2 (ja) 2001-08-08 2009-08-19 トビラ セラピューティクス インク 二環性化合物、その製造法および用途
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
EP1523310A2 (en) 2002-07-09 2005-04-20 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
WO2005070938A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
WO2006039663A2 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals, Inc Methods for the administration of iloperidone
EP2708531A1 (en) 2004-10-13 2014-03-19 Pharmacia & Upjohn Company LLC Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide
CA2586761A1 (en) * 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
US20070088082A1 (en) * 2005-09-28 2007-04-19 Judith Aronhime Polymorphic forms of ladostigil tartrate
WO2007040995A1 (en) * 2005-10-03 2007-04-12 Mallinckrodt Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
EP2142197A4 (en) * 2007-03-30 2010-11-10 Amicus Therapeutics Inc PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS
US9056101B2 (en) 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
WO2009117122A2 (en) 2008-03-19 2009-09-24 Existence Genetics Llc Genetic analysis
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
LT2733142T (lt) 2009-11-27 2018-10-10 Adverio Pharma Gmbh Metil-{4,6-diamino-2-[1-(2-fluorbenzil)-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamato, skirto naudoti kaip farmaciškai veiksmingo ingrediento, gamybos būdas
CA2839621A1 (en) 2011-06-21 2012-12-27 Novartis Ag Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
BR112012012947B8 (pt) 2021-05-25
CL2012001348A1 (es) 2012-08-24
IL219892A0 (en) 2012-07-31
US20160166542A1 (en) 2016-06-16
CN102712629B (zh) 2016-10-12
ME02477B (me) 2017-02-20
MY192644A (en) 2022-08-29
UA113491C2 (xx) 2017-02-10
US20160120842A1 (en) 2016-05-05
ECSP12011926A (es) 2012-07-31
TN2012000237A1 (en) 2013-12-12
US11458119B2 (en) 2022-10-04
HK1203485A1 (zh) 2015-10-30
HUE045784T2 (hu) 2020-01-28
CN105753846B (zh) 2019-11-15
PL2504332T5 (pl) 2021-08-23
JP6370264B2 (ja) 2018-08-08
TW201737910A (zh) 2017-11-01
EP2796457A1 (en) 2014-10-29
NZ600155A (en) 2014-10-31
HRP20161038T1 (hr) 2016-10-21
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
LT2796457T (lt) 2016-09-12
TWI656873B (zh) 2019-04-21
EP3599237B1 (en) 2021-03-24
DOP2012000141A (es) 2012-09-30
ES2875382T3 (es) 2021-11-10
EP2796457B1 (en) 2016-05-18
TW201130822A (en) 2011-09-16
HUE029371T2 (en) 2017-02-28
PL3599237T3 (pl) 2021-09-27
TW201639562A (zh) 2016-11-16
SI2796457T1 (sl) 2016-10-28
EP3133070B1 (en) 2019-08-14
ES2493940T3 (es) 2014-09-12
PL2796457T3 (pl) 2017-04-28
EP2504332B1 (en) 2014-06-04
AU2010324810A1 (en) 2012-06-07
AU2016202591A1 (en) 2016-05-19
KR20150125734A (ko) 2015-11-09
HRP20191647T1 (hr) 2019-12-13
CN112521367A (zh) 2021-03-19
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
EP3133070A1 (en) 2017-02-22
DOP2016000250A (es) 2017-02-15
CN102712629A (zh) 2012-10-03
PT2796457T (pt) 2016-07-14
JP2019001809A (ja) 2019-01-10
CA3075788A1 (en) 2011-06-03
US20230172903A1 (en) 2023-06-08
BR112012012947B1 (pt) 2021-04-06
CN105777707B (zh) 2020-10-13
CA2781676C (en) 2020-05-05
JP2023116764A (ja) 2023-08-22
CA2781676A1 (en) 2011-06-03
US20130137743A1 (en) 2013-05-30
NZ715108A (en) 2017-06-30
US10888547B2 (en) 2021-01-12
DK2504332T4 (da) 2021-06-07
KR20200013105A (ko) 2020-02-05
GT201200161A (es) 2014-01-27
SMT201600273B (it) 2016-08-31
EP2504332B2 (en) 2021-03-17
LT3133070T (lt) 2019-11-11
JP2015212291A (ja) 2015-11-26
BR112012012947A2 (pt) 2017-03-01
JP2020189873A (ja) 2020-11-26
IL260299A (en) 2018-08-30
CN112521367B (zh) 2024-01-02
PL2504332T3 (pl) 2014-10-31
MX2012006083A (es) 2012-06-19
NI201200096A (es) 2012-10-30
DK2504332T3 (da) 2014-08-25
KR20220162824A (ko) 2022-12-08
WO2011066352A1 (en) 2011-06-03
US20210369672A1 (en) 2021-12-02
EA201270646A1 (ru) 2013-01-30
HRP20140780T1 (en) 2014-11-07
CL2016002589A1 (es) 2017-05-19
EA201592195A1 (ru) 2016-04-29
SI2504332T2 (sl) 2021-08-31
CY1117996T1 (el) 2017-05-17
MY160542A (en) 2017-03-15
AU2016202591B2 (en) 2017-11-30
EP3896069A1 (en) 2021-10-20
ECSP18063798A (es) 2020-02-28
CR20120277A (es) 2012-09-05
SI2504332T1 (sl) 2014-09-30
EA201890254A2 (ru) 2018-10-31
EA023923B1 (ru) 2016-07-29
HRP20140780T4 (hr) 2021-08-06
SI3133070T1 (sl) 2019-11-29
JP6452635B2 (ja) 2019-01-16
PT3133070T (pt) 2019-11-11
SG10201407881WA (en) 2015-01-29
WO2011066352A8 (en) 2011-08-11
JP2013512252A (ja) 2013-04-11
PH12015502514A1 (en) 2016-08-15
IL310635A (en) 2024-04-01
PT3599237T (pt) 2021-04-28
JP2016138124A (ja) 2016-08-04
EA201890254A3 (ru) 2019-02-28
ES2754398T3 (es) 2020-04-17
JP7150528B2 (ja) 2022-10-11
DK2796457T3 (da) 2016-08-29
CY1122698T1 (el) 2021-03-12
CN112521366A (zh) 2021-03-19
RS53503B1 (en) 2015-02-27
IL283935A (en) 2021-07-29
PL3133070T3 (pl) 2020-01-31
CA3140959A1 (en) 2011-06-03
KR20120115972A (ko) 2012-10-19
SG10201800136QA (en) 2018-02-27
EP2504332A1 (en) 2012-10-03
AU2017265180A1 (en) 2017-12-14
AR079152A1 (es) 2011-12-28
HK1172031A1 (en) 2013-04-12
MA33838B1 (fr) 2012-12-03
RS53503B2 (sr) 2021-07-30
RS54978B1 (sr) 2016-11-30
CY1115880T1 (el) 2017-01-25
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
EA029990B1 (ru) 2018-06-29
PT2504332E (pt) 2014-09-02
ES2586947T3 (es) 2016-10-19
EP3599237A1 (en) 2020-01-29
RS59543B1 (sr) 2019-12-31
AR121612A2 (es) 2022-06-22
PE20171255A1 (es) 2017-08-28
AU2017265180B2 (en) 2019-08-01
ES2493940T5 (es) 2021-11-23
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
CA3075788C (en) 2021-12-21
TWI586663B (zh) 2017-06-11
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
KR20180049255A (ko) 2018-05-10

Similar Documents

Publication Publication Date Title
DK3133070T3 (da) Eliglustat (genz 112638) som inhibitor af glucosylceramidsyntase til anvendelse i en fremgangsmåde til behandling af fabrys eller gauchers sygdom, hvilken fremgangsmåde omfatter justering af den individuelle terapeutiske dosis i forhold til patientens p-450-metabolisme
NO20085004L (no) Radioaktivt merkede dihydrotetrabenazinderivater og deres anvendelse som avbildningsmidler
CR11731A (es) Composiciones y procedimientos para su preparación y uso
DK1984357T3 (da) 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
DK2040713T3 (da) Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
NO20082395L (no) Krystallinske former av 1'-(1-metyl)-4'-[(2-fluor-4-metoksyfenyl)metyl]-5'-metyl-1H-pyrazol-3'-O-beta-D-glucopyranosid, en fremstillingsmetode og anvendelse av denne for fremstilling av medikamenter
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UY32062A (es) Inhibidores de beta-secretasa
NO20052668D0 (no) Umiddelbart avgivende doseringsform som har kapsel med apninger i denne
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
BRPI0718927A2 (pt) Método de imunização contra os quatro sorotipos da dengue.
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
DK3309139T3 (da) Process for the preparation of 2,3,3,3-trifluoropropene
CL2007003158A1 (es) Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20083836L (no) N-hydroksyakrylamidforbindelser
DK2350026T3 (da) Sulfoximinsubstituerede anilinopyrimidinderativer som cdk-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
DK1954251T3 (da) Sammensætning med langvarig frigivelse, som har jernsalt som aktiv bestanddel, fremgangsmåde til fremstilling deraf og anvendelse deraf
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.